Verona Pharma (VRNA)
(Real Time Quote from BATS)
$37.21 USD
-1.18 (-3.07%)
Updated Nov 6, 2024 03:12 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
VRNA 37.21 -1.18(-3.07%)
Will VRNA be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for VRNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VRNA
Recent Price Trend in Verona Pharma (VRNA) is Your Friend, Here's Why
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma
VRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
Wall Street Analysts Think Verona Pharma (VRNA) Could Surge 25.25%: Read This Before Placing a Bet
Verona Pharma (VRNA) Is a Great Choice for 'Trend' Investors, Here's Why
Other News for VRNA
Verona Pharma management to meet with BTIG
Verona Pharma management to meet with BTIG
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Verona Pharma PLC CFO Mark Hahn Sells 129,672 Shares